Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederema.europa.eu
Human medicines: European public assessment reports (EPARs)
Get the latest updates from Human medicines: European public assessment reports (EPARs) directly as they happen.
Follow now 282 followers
Latest posts
Last updated about 9 hours ago
Human medicines European public assessment report (EPAR): Anagrelide Viatris (previously Anagrelide Mylan), anagrelide, Date of authorisation: 15/02/2018, Revision: 12, Status: Authorised
about 9 hours ago
Human medicines European public assessment report (EPAR): Anagrelide Viatris (previously Anagrelide Mylan)...
Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Date of authorisation: 11/02/2021, Revision: 10, Status: Authorised
about 9 hours ago
Human medicines European public assessment report (EPAR): Tukysa, tucatinib, Date of authorisation...
Human medicines European public assessment report (EPAR): Elucirem, gadopiclenol, Date of authorisation: 07/12/2023, Revision: 3, Status: Authorised
about 9 hours ago
Human medicines European public assessment report (EPAR): Elucirem, gadopiclenol, Date of authorisation...
Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Date of authorisation: 25/08/2022, Revision: 7, Status: Authorised
about 10 hours ago
Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Date of authorisation...
Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 4, Status: Authorised
about 10 hours ago
Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab...
Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Refused
about 11 hours ago
Human medicines European public assessment report (EPAR): Kizfizo, temozolomide, Status: Refused
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 49, Status: Authorised
about 11 hours ago
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation...
Human medicines European public assessment report (EPAR): Ohtuvayre, ensifentrine, Status: Application withdrawn
about 13 hours ago
Human medicines European public assessment report (EPAR): Ohtuvayre, ensifentrine, Status: Application withdrawn
Human medicines European public assessment report (EPAR): Insulin Aspart Injection, insulin aspart, Status: Application withdrawn
about 13 hours ago
Human medicines European public assessment report (EPAR): Insulin Aspart Injection, insulin aspart...
Summary of opinion: Xerava, 13/11/2025 Positive
about 13 hours ago
Summary of opinion: Xerava, 13/11/2025 Positive
Human medicines European public assessment report (EPAR): Aqneursa, L-acetylleucine, Status: Opinion
about 13 hours ago
Human medicines European public assessment report (EPAR): Aqneursa, L-acetylleucine, Status: Opinion
Human medicines European public assessment report (EPAR): Hetlioz, tasimelteon, Date of authorisation: 03/07/2015, Revision: 9, Status: Authorised
about 13 hours ago
Human medicines European public assessment report (EPAR): Hetlioz, tasimelteon, Date of authorisation...